Article information
Full text is only aviable in PDF
Bibliografía
[1.]
K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, et al.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Am J Respir Crit Care Med, 176 (2007), pp. 532-555
[2.]
S.S. Salvi, P.J. Barnes.
Chronic obstructive pulmonary disease in non-smokers.
Lancet, 374 (2009), pp. 733-743
[3.]
C. Svanes, J. Sunyer, E. Plana, S. Dharmage, J. Heinrich, D. Jarvis, et al.
Early life origins of chronic obstructive pulmonary disease.
Thorax, 65 (2010), pp. 14-20
[4.]
D. Massaro, G. DeCarlo Massaro.
Lung Development, Lung Function, and Retinoids.
N Engl J Med, 362 (2010), pp. 1829-1831
[5.]
D. Gonzales, S.I. Rennard, M. Nides, C. Oncken, S. Azoulay, C.B. Billing, et al.
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
JAMA, 296 (2006), pp. 47-55
[6.]
D. Jorenby, S. Leischow, A. Nides, S. Rennard, J.A. Johnston, D. Pharm, et al.
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
N Engl J Med, 340 (1999), pp. 685-691
[7.]
P. Tonnesen, L. Carrozzi, K.O. Fagerstrom, C. Gratziou, C. Jimenez-Ruiz, S. Nardini, et al.
Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy.
Eur Respir J, 29 (2007), pp. 390-417
[8.]
A. Punturieri, E. Szabo, T.L. Croxton, S.D. Shapiro, S.M. Dubinett.
Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.
J Natl Cancer Inst, 101 (2009), pp. 554-559
[9.]
J.F. Donohue, C. Fogarty, J. Lotvall, D.A. Mahler, H. Worth, A. Yorgancioglu, et al.
Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium.
Am J Respir Crit Care Med, 182 (2010), pp. 155-162
[10.]
P. Chanez, P.S. Burge, R. Dahl, J. Creemers, A. Chuchalin, R. Lamarca, et al.
Aclidinium bromide provides long-acting bronchodilation in patients with COPD.
Pulm Pharmacol Ther, 23 (2010), pp. 15-21
[11.]
J. Vestbo, J.A. Anderson, P.M. Calverley, B. Celli, G.T. Ferguson, G. Jenkins, et al.
Adherence to inhaled therapy, mortality and hospital admission in COPD.
Thorax, 64 (2009), pp. 939-943
[12.]
L. Fabbri, M.P.M. Calverley, J.L. Izquierdo-Alonso, D.S. Bundschuh, M. Brose, F.J. Martinez, et al.
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Lancet, 374 (2009), pp. 695-703
[13.]
P.M. Calverley, K.F. Rabe, U.M. Goehring, S. Kristiansen, L.M. Fabbri, F.J. Martinez.
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Lancet, 374 (2009), pp. 685-694
[14.]
K.F. Rabe, E.D. Bateman, D. O’Donnell, S. Witte, D. Bredenbroker, T.D. Bethke.
Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet, 366 (2005), pp. 563-571
[15.]
A. Agusti.
Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don’t Know (but Should).
Proceedings of the American Thoracic Society, pp. 522-525
[16.]
L.M. Fabbri, K.F. Rabe.
From COPD to chronic systemic inflammatory syndrome?.
Lancet, 370 (2007), pp. 797-799
[17.]
A. Agusti, A. Thomas.
Neff lecture, Chronic obstructive pulmonary disease: a systemic disease.
Proc Am Thorac Soc, 3 (2006), pp. 478-481
[18.]
S. Sethi, P.W. Jones, M.S. Theron, M. Miravitlles, E. Rubinstein, E.A. Wedzicha, R. Wilson.
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
Respir Res, 11 (2010), pp. 10
[19.]
M. Cosio, M. Saetta, A. Agusti.
Immunological aspects of COPD.
N Engl J Med, 360 (2009), pp. 2445-2454
[20.]
M.D. Roth, J.E. Connett, J.M. D’Armiento, R.F. Foronjy, P.J. Friedman, Goldin, et al.
Feasibility of Retinoids for the Treatment of Emphysema Study.
Chest, 130 (2006), pp. 1334-1345
[21.]
E.P. Ingenito, R.L. Berger, A.C. Henderson, J.J. Reilly, L. Tsai, A. Hoffman.
Bronchoscopic lung volume reduction using tissue engineering principles.
Am J Respir Crit Care Med, 167 (2003), pp. 771-778
[22.]
G.B. Mancini, M. Etminan, B. Zhang, L.E. Levesque, J.M. Fitzgerald, J.M. Brophy.
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.
J Am Coll Cardiol, 47 (2006), pp. 2554-2560
[23.]
P.M.A. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, P.W. Jones, et al.
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease.
N Engl J Med, 356 (2007), pp. 775-789
[24.]
P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, H. Olsson.
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
Eur Respir J, 22 (2003), pp. 912-919
[25.]
D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, et al.
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease.
N Engl J Med, 359 (2008), pp. 1543-1554
[26.]
A.L. Ries, R.M. Kaplan, T.M. Limberg, L.M. Prewitt.
Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease.
Ann Intern Med, 122 (1995), pp. 823-832
[27.]
National Emphysema Treatment Trial Research Group.
A Randomized Trial Comparing Lung-Volume-Reduction Surgery with Medical Therapy for Severe Emphysema.
N Engl J Med, 348 (2003), pp. 2059-2073
[28.]
N.R. Anthonisen, M.A. Skeans, R.A. Wise, J. Manfreda, R.E. Kanner, J.E. Connett.
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Ann Intern Med, 142 (2005), pp. 233-239
[29.]
B.R. Celli, N.E. Thomas, J.A. Anderson, G.T. Ferguson, C.R. Jenkins, P.W. Jones, et al.
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Am J Respir Crit Care Med, 178 (2008), pp. 332-338
[30.]
Nocturnal Oxygen Therapy Trial Group.
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial.
Ann Intern Med, 93 (1980), pp. 391-398
[31.]
Report of the Medical Research Council Working Party.
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema.
Lancet, i (1981), pp. 681-685
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
